Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: A prospective, randomized, multi-center, double-blind, placebo-controlled study

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 4, 2011, Pages 320-325

  Lee, S H ^a   Chung, B H ^a   Kim, S J ^b   Kim, J H ^c   Kim, J C ^d   Lee, J Y ^b  

^a Yonsei University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

blocker; anticholinergics; BPH; combination therapy; overactive bladder

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PLACEBO; TOLTERODINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; KOREA; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERACTIVE BLADDER; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; UROFLOWMETRY; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 80955158728     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.22     Document Type: Article

References (28)

1. Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 2008; 102: 981-986.
2. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001; 58: 5-16; discussion 16. (Pubitemid 34007591)
3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al. Population-based survey of urinary incontinence, over-active bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-1314 discussion 1314-5.
4. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651-658. (Pubitemid 43374725)
5. de Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 2003; 169: 535-539. (Pubitemid 36132980)
6. Coyne KS, Matza L, Thompson C, Kopp Z, Jumadilova Z, Brubaker L. From an OAB patient perspective: health-related quality of life improves when frequency and urgency improve. In: 35th Annual Meeting of the International Continence Society; August 28-September 2, 2005; Montreal, Quebec.
7. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079-1086. (Pubitemid 43673993)
8. Takei M, Homma Y. Long-term safety, toloerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanease patients. Int J Urol 2005; 12: 456-464. (Pubitemid 41015153)
9. Blaivas JG, Marks BK, Weiss JP, Panagopoulos G, Somaroo C. Differential diagnosis of overactive bladder in men. J Urol 2009; 182: 2814-2817.
10. Ameda K, Sullivan MP, Bae RJ, Yalla SV. Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. J Urol 1999; 162: 142-146. (Pubitemid 29420898)
11. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150: 351-358. (Pubitemid 23215869)
12. Hofner K, Burkart M, Jacob G, Jonas U. Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 2010; 28: 353-357.
13. Diokno A, Sand P, Labasky R, Sieber P, Antoci J, Leach G et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002; 34: 43-49. (Pubitemid 36090223)
14. Haab F, Cardozo L, Chapple C, Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-384. (Pubitemid 40248865)
15. Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006; 98: 1025-1032. (Pubitemid 44536453)
16. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296: 2319-2328. (Pubitemid 44749359)
17. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178. (Pubitemid 34195211)
18. Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol 2009; 43: 307-314.
19. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-336. (Pubitemid 44175300)
20. Yamaguchi O, Aikawa K, Shishido K, Nomiya M. Place of overactive bladder in male lower urinary tract symptoms. World J Urol 2009; 27: 723-728.
21. Lee SH, Kim JC, Lee KS, Lee JG, Park CH, Hong SJ et al. The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting. Yonsei Med J 2010; 51: 432-437.
22. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999-1004; discussion 1004. (Pubitemid 43200054)
23. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 2273-2275; discussion 2275-2276. (Pubitemid 41611800)
24. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-820. (Pubitemid 39472476)
25. Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174: 1334-1338. (Pubitemid 41318723)
26. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005; 24: 215-225. (Pubitemid 40617094)
27. Brown JS, McNaughton KS, Wyman JF, Burgio KL, Harkaway R, Bergner D et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 2003; 61: 802-809. (Pubitemid 36384977)
28. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998; 280: 1995-2000.